All patients had low levels of AF-activity in serum at baseline. During treatment with Salovum®, the mean level increased slightly. AF-activity was also significantly higher after treatment with SPC-Flakes®. In four of the five patients such AF levels in plasma were detected which has in other studies correlated well with positive treatment effects of diarrhoea.
Although these patients had been given optimal medical therapy, an added positive effect could be seen with the addition of the AF-treatment. Treatment with Salovum® was well tolerated by all patients. The two patients with MTC and fully intact intestines responded best to SPC-diet with the highest AF levels, reaching over 1 unit/ml plasma, after completed treatment.
The positive response to Salovum® indicates that AF protein has a local effect in the intestine, directly interacting with the receptors and its binding proteins in mucosal cells. Therapy with Salovum® may hence be a suitable treatment alternative for patients with difficulties ingesting large amounts of specially produced cereals.
Laurenius, Wängberg, Lange, Jennische, Lundgren and Bosaeus, Antisecretory factor counteracts secretory diarrhoea of endocrine origin, Clinical Nutrition, 2003; 22(6):549-542, view link
Treatment with Salovum® in children with unspecified diarrhoea
A clinical study with Salovum® in Pakistan has also been made in children with severe diarrhoea of acute or prolonged character. 240 children aged 6-24 months were randomised to treatment with 2g Salovum® or placebo in addition to an oral rehydration salt solution every 5 h for three days. In the treatment group with acute diarrhoea (less than 5 days), children treated with Salovum® had a significant improvement of 82,8% compared to 54,4% in the control group (p<0,001).
Among children with diarrhoea for more than 7 days, the children treated with Salovum had a significant improvement of their condition of 90,9% compared to 63,2% of the controls (p=0,0011).
The authors conclude that Salovum® is a very appealing treatment option for the future, both in acute and chronic diarrhoea. The optimal dose of Salovum® is not known and because a low dose was used, it is likely that a higher dose in some patients could have given a further improved result. It is also likely that the patients in the study were infected with different agents and it is shown that Salovum® protects against diarrhoeal diseases induced by non-specific nature.
Salovum® may have a significant impact among populations with a high morbidity and mortality in these diseases. Moreover, it can be followed up with SPC-Flakes® which stimulates the body to produce AF. SPC-Flakes® can also be used for prophylaxis in highly exposed populations, especially during the diarrhoea season.
Zaman, Mannan, Lange, Lönnroth and Hanson, B221, a medical food containing antisecretory factor reduces child diarrhoea: a placebo controlled trial, Acta Paediatrica Scandinavia 96:1655-1659, 2007, view link